Test Report Status

<u>Final</u>



**Biological Reference Interval** Units



PATIENT NAME : BHAWNA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		
	i	i

Results

	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	11.1 Low	12.0 - 15.0	g/dL
METHOD : CYANMETHEMOGLOBIN METHOD			
RED BLOOD CELL (RBC) COUNT	3.61 Low	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT	5.90	4.0 - 10.0	thou/µL
PLATELET COUNT	259	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	33.7 Low	36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	93.3	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	30.8	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	33.1	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED PARAMETER	17.2 High	11.6 - 14.0	%
MENTZER INDEX	25.8		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	11.4 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	66	40 - 80	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	MPEDENCE		
LYMPHOCYTES	23	20 - 40	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	MPEDENCE		
MONOCYTES	8	2.0 - 10.0	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	MPEDENCE		
EOSINOPHILS	3	1.0 - 6.0	%
BASOPHILS	0	0 - 1	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CELLS I	MPEDENCE		
ABSOLUTE NEUTROPHIL COUNT	3.89	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	1.36	1.0 - 3.0	thou/µL

Deraralit

Dr.Pranjali Vasisht LAB HEAD



DR.CHANDNI GARG CONSULTANT PATHOLOGIST Page 1 Of 16



Vie<u>w</u> Details







PATIENT NAME : BHAWNA	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 00	80WI008081 AGE/SEX	:36 Years Female	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : BH,	AWF20088780 DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED	: 23/09/2023 09:36:29	
NEW DELHI 110030	ABHA NO :	REPORTED	:23/09/2023 16:09:17	
8800465156				
Test Report Status <u>Final</u>	Results	Biological Reference	ce Interval Units	
ABSOLUTE MONOCYTE COUNT	0.47	0.2 - 1.0	thou/µL	
ABSOLUTE EOSINOPHIL COUNT	0.18	0.02 - 0.50	thou/µL	
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL	
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.9			

METHOD : CALCULATED PARAMETER

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFRENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR =

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Concult

**Dr.Pranjali Vasisht** LAB HEAD

Chardni garg

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST





Page 2 Of 16

View Details







PATIENT NAME : BHAWNA	REF. DOCTOR : S	ELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

**Biological Reference Interval** Units

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE	0 - 20 mm at 1 hr Non-diabetic Adult < 5.7 % Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = $6.5$ Therapeutic goals: < 7.0	
ERYTHROCYTE SEDIMENTATION RATE (ESR BLOOD	),WHOLE		
E.S.R	22 High	0 - 20	mm at 1 hr
METHOD : MODIFIED WESTERGREN			
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDT BLOOD	TA WHOLE		
HBA1C	5.3		%
			6.5
		1 5	
		Action suggested : > 8.0 (ADA Guideline 2021)	
ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL

#### Interpretation(s)

ERTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

#### TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

Chardni Garg

Dearaht

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD





View Report

Page 3 Of 16







**PATIENT NAME : BHAWNA REF. DOCTOR : SELF** CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WI008081 AGE/SEX :36 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : BHAWF20088780 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/09/2023 09:36:29 DELHI ABHA NO REPORTED :23/09/2023 16:09:17 : NEW DELHI 110030 8800465156 **Test Report Status** Results **Biological Reference Interval** <u>Final</u> Units

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

HbA1c Estimation can get affected due to : 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Chardni Garg

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST Desault


Dr.Pranjali Vasisht LAB HEAD















PATIENT NAME : BHAWNA	<b>REF. DOCTOR :</b> S	ELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		

Test Report Status <u>Final</u> Results

**Biological Reference Interval** Units

## IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE A METHOD : SLIDE AGGLUTINATION RH TYPE POSITIVE METHOD : SLIDE AGGLUTINATION

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Concalit

Dr.Pranjali Vasisht LAB HEAD

Chardni garg

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST





liew Repor

Page 5 Of 16







PATIENT NAME : BHAWNA	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		
<u></u>		

...............

Results

**Biological Reference Interval** Units

Patient Ref. No. 775000004805858

	E	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEA	ALTH CHECKUP BEL	OW 40FEMALE		
GLUCOSE FASTING, FLUORID	E PLASMA			
FBS (FASTING BLOOD SUGA METHOD : HEXOKINASE	R)	80	74 - 106	mg/dL
GLUCOSE, POST-PRANDIAL,	PLASMA			
PPBS(POST PRANDIAL BLOO		SAMPLE NOT RECEIVED	Non-Diabetes 70 - 140	mg/dL
METHOD : HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL		227 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE, EST	ERASE,PEROXIDASE	o. /		<i>(</i> ))
TRIGLYCERIDES		84	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY				
HDL CHOLESTEROL		56	< 40 Low	mg/dL
METHOD : DIRECT MEASURE - PEG			>/=60 High	
CHOLESTEROL LDL		154 High	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
METHOD : CHOLESTEROL OXIDASE, EST	ERASE, PEROXIDASE			
NON HDL CHOLESTEROL		56	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER				
Chardni Garg	Deraralit			Page 6 Of 16
DR.CHANDNI GARG CONSULTANT PATHOLOGIST	Dr.Pranjali Vasish LAB HEAD	t		
PERFORMED AT :			View De	etails View Report





**PATIENT NAME : BHAWNA REF. DOCTOR : SELF** CODE/NAME & ADDRESS : C000138383 ACCESSION NO : 0080WI008081 AGE/SEX :36 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : BHAWF20088780 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 23/09/2023 09:36:29 DELHI REPORTED :23/09/2023 16:09:17 ABHA NO : NEW DELHI 110030 8800465156 Biological Reference Interval **Test Report Status Final** Results Units

VERY LOW DENSITY LIPOPROTEIN	16.8	Desirable value : mg/dL 10 - 35
METHOD : CALCULATED PARAMETER		
CHOL/HDL RATIO	4.1	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk
METHOD : CALCULATED PARAMETER		
LDL/HDL RATIO	2.8	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk
METHOD : CALCULATED PARAMETER		

## Interpretation(s)

rget and Non


	Serum lipid profile is m HDL-C as co-primary tr			pid Association	of India recommends LDL-C as primary target
	1 2	•	erosclerotic cardiovascular di	sease) by Lipid	Association of India
	Risk Category			, <b>.</b>	
	Extreme risk group	A.CAD with	n > 1 feature of high risk group		
		B. CAD with	h > 1 feature of Very high risk g	group or recurre	ent ACS (within 1 year) despite LDL-C < or =
		50 mg/dl or	polyvascular disease		
	Very High Risk	1. Establishe	ed ASCVD 2. Diabetes with 21	major risk facto	rs or evidence of end organ damage 3.
		Familial Ho	mozygous Hypercholesterolemi	a	
	High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ			
		damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
		Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
	Moderate Risk	ate Risk 2 major ASCVD risk factors			
	Low Risk 0-1 major ASCVD risk factors				
	Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors				
	1. Age $>$ or $= 45$ years in males and $>$ or $= 55$ years in females 3. Current Cigarette smoking or tobacco use			garette smoking or tobacco use	
	2. Family history of premature ASCVD 4. High blood pressure			l pressure	
	5. Low HDL				
]	Newer treatment goals	and statin in	itiation thresholds based on th	e risk categori	es proposed by LAI in 2020.
	Risk Group		Treatment Goals		Consider Drug Therapy

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30 )	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100

Chardni garg

Concult

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST



Page 7 Of 16





View <u>Report</u>







PATIENT NAME : BHAWNA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : BHAWF20088780	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		

Test Report Status	Final	Results
rest hepoirt status	<u>i mai</u>	Results

**Biological Reference Interval** Units

Moderate Risk	<100	<130	>OR=100	>OR=130	
Low Risk	<100	<130	>OR=130*	>OR=160	
*After an adequate non-pharmacolog <b>References:</b> Management of Dyslipic India. Current Vascular Pharmacolog <b>LIVER FUNCTION PROFILE, SE</b>	laemia for the Prevent y, 2022, 20, 134-155.	ion of Stroke: Clinical P	ractice Recommend	ations from the Lipid A	ssociation of
BILIRUBIN, TOTAL METHOD : DIAZONIUM ION, BLANKED (RC	OCHE)	0.28	UPTO 1.2		mg/dL
BILIRUBIN, DIRECT METHOD : DIAZOTIZATION		0.10	0.00 - 0.3	30	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER		0.18	0.00 - 0.0	60	mg/dL
TOTAL PROTEIN METHOD : BIURET		7.4	6.6 - 8.7		g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN		4.7	3.97 - 4.9	94	g/dL
GLOBULIN		2.7	2.0 - 4.0 Neonates Pre Matur 0.29 - 1.0	re:	g/dL
METHOD : CALCULATED PARAMETER					
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER		1.7	1.0 - 2.0		RATIO
ASPARTATE AMINOTRANSFER	ASE(AST/SGOT)	18	0 - 32		U/L
ALANINE AMINOTRANSFERAS		18	0 - 31		U/L
ALKALINE PHOSPHATASE METHOD : PNPP - AMP BUFFER		99	35 - 105		U/L
GAMMA GLUTAMYL TRANSFER METHOD : GAMMA GLUTAMYLCARBOXY 4N	· · · ·	15	5 - 36		U/L
LACTATE DEHYDROGENASE METHOD : LACTATE -PYRUVATE		194	135 - 214	4	U/L
BLOOD UREA NITROGEN (BUN	), SERUM				
BLOOD UREA NITROGEN METHOD : UREASE - UV		8	6 - 20		mg/dL
CREATININE, SERUM					
CREATININE		0.57	0.50 - 0.9	90	mg/dL

Chardoni Gory

Concure

DR.CHANDNI GARG CONSULTANT PATHOLOGIST Dr.Pranjali Vasisht LAB HEAD

Page 8 Of 16 -٠.

Vie<u>w</u> Details







PATIENT NAME : BHAWNA		REF. DOCTOR : S	ELF	
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>008</b> PATIENT ID : BHA CLIENT PATIENT ID: ABHA NO :	WF20088780	AGE/SEX : 36 Years DRAWN : RECEIVED : 23/09/20 REPORTED :23/09/20	
Test Report Status <u>Final</u>	Results	Biological F	Reference Interval	Units
METHOD : ALKALINE PICRATE-KINETIC BUN/CREAT RATIO	14.04		20	
BUN/CREAT RATIO METHOD : CALCULATED PARAMETER URIC ACID, SERUM	14.04	5.00 - 15.0	JU	
URIC ACID METHOD : URICASE, COLORIMETRIC TOTAL PROTEIN, SERUM	4.6	2.4 - 5.7		mg/dL
TOTAL PROTEIN METHOD : BIURET ALBUMIN, SERUM	7.4	6.6 - 8.7		g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.7	3.97 - 4.94	4	g/dL
GLOBULIN	2.7	2.0 - 4.0 Neonates - Pre Mature 0.29 - 1.04		g/dL
METHOD : CALCULATED PARAMETER				
ELECTROLYTES (NA/K/CL), SERUM	120	100 145		mmal/l
SODIUM, SERUM METHOD : ISE INDIRECT	138	136 - 145		mmol/L
POTASSIUM, SERUM METHOD : ISE INDIRECT	4.68	3.5 - 5.1		mmol/L
CHLORIDE, SERUM METHOD : ISE INDIRECT	104	98 - 107		mmol/L
Interpretation(s)				
Sodium Potassium	CI	loride		

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST

**PERFORMED AT :** Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Concure

Dr.Pranjali Vasisht LAB HEAD





Page 9 Of 16

View Details







PATIENT NAME : BHAWNA	<b>REF. DOCTOR :</b> S	SELF
	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : BHAWF20088780	DRAWN :
DELHI		RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		

Results

**Biological Reference Interval** Units

Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

#### Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed. Alimentary Hypoglycemia. Increased insulin response & sensitivity etc.

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic

Chardni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD





View Report

Page 10 Of 16

View Details







PATIENT NAME : BHAWNA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138383 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO: <b>0080WI008081</b> PATIENT ID : BHAWF20088780 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Female DRAWN : RECEIVED :23/09/2023 09:36:29 REPORTED :23/09/2023 16:09:17
Test Report Status Final	Results Biologica	Reference Interval Units

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels

(hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Chardni Garg

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD







View Report

/iew Details







PATIENT NAME : BHAWNA	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS :C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		
(	i	i

Results

**Biological Reference Interval** Units

### **CLINICAL PATH - URINALYSIS**

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR

SAMPLE NOT RECEIVED

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Deraulit

Dr.Pranjali Vasisht LAB HEAD





Page 12 Of 16

View Details







PATIENT NAME : BHAWNA	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000138383	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		

Results

Biological Reference Interval Units

$\sim$	/тс		GY
		LO	U D

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR TEST METHOD OTHER MALIGNANT NEOPLASMS

SAMPLE NOT RECEIVED SAMPLE NOT RECEIVED

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST

PERFORMED AT : Agilus Diagnostics Ltd. 24 Sco, Sector 11 D Chandigarh, 160011 Punjab, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Deraulit

Dr.Pranjali Vasisht LAB HEAD





Page 13 Of 16

View Details







PATIENT NAME : BHAWNA	REF. DOCTOR : S	ELF
	ACCESSION NO : 0080WI008081	AGE/SEX : 36 Years Female
	PATIENT ID : BHAWF20088780	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 23/09/2023 09:36:29
NEW DELHI 110030	ABHA NO :	REPORTED :23/09/2023 16:09:17
8800465156		
(	1	

Results

**Biological Reference Interval** Units

#### **SPECIALISED CHEMISTRY - HORMONE** MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE THYROID PANEL, SERUM ng/dL T3 111.90 Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester:135.0 - 262.0 METHOD : ECLIA 7.77 T4 Non-Pregnant Women µg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70 METHOD : ECLIA 5.390 High µIU/mL TSH (ULTRASENSITIVE) Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

METHOD : ECLIA

## Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No. TSH Total T4 FT4 Total T3	Possible Conditions
-----------------------------------	---------------------

Chardni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD





View Repor

Page 14 Of 16

View Details

Patient Ref. No. 775000004805858





## DATTENT NAME . DUAWNA

PATIENT NAME : BHAWNA	I NAME : BHAWNA REF. DOCTOR			
		AGE/SEX : 36 Years Female		
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : BHAWF20088780 CLIENT PATIENT ID:	DRAWN : RECEIVED : 23/09/2023 09:36:29		
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :23/09/2023 16:09:17		

#### **Test Report Status** <u>Final</u>

Results

**Biological Reference Interval** Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
	_				Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, Iodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

Chardni garg

**DR.CHANDNI GARG** CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD





Page 15 Of 16

Details







PATIENT NAME : BHAWNA	<b>REF. DOCTOR</b> : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : BHAWF20088780 CLIENT PATIENT ID:	AGE/SEX : 36 Years Female DRAWN : RECEIVED : 23/09/2023 09:36:29 REPORTED : 23/09/2023 16:09:17
Test Report Status Final	Results Biological	Reference Interval Units

## **CONDITIONS OF LABORATORY TESTING & REPORTING**

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

### Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Chardni Garg

**PERFORMED AT:** 

DR.CHANDNI GARG CONSULTANT PATHOLOGIST



Dr.Pranjali Vasisht LAB HEAD





View Repor

Page 16 Of 16

View Details

